Drug assessment at a glance: A25-155[1]

Cemiplimab (cutaneous squamous cell carcinoma, adjuvant)

24 August 2026

[1] This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A25-155. The G-BA decides on the added benefit.

Research question for the benefit assessment

Population	Adult patients with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation; adjuvant treatment
Intervention	cemiplimab
Comparator	Watchful waiting
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects

	Size of the effects		Informative value of the effects	
Mortality	∅		–	
Morbidity	∅		–	
Symptoms	∅		–	
Health-related quality of life	∅		–	
Side effects	∅		–	
	∅	No (suitable) data	–	Not applicable
	↔	No advantage or disadvantage	★	Low
	↑ / ↓	Small advantage/disadvantage	★★	Moderate
	↑↑ / ↓↓	Moderate advantage/disadvantage	★★★	High
	↑↑↑ / ↓↓↓	Large advantage/disadvantage		

Overall: No advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects

- Evidence base: double-blind, randomized C-POST study comparing cemiplimab (N = 209) with placebo (N = 206)
- No suitable data were available. The observation period of the C-POST study did not adequately cover the high-risk period for recurrence following the completion of treatment with cemiplimab. Consequently, it was not possible to carry out an overall assessment of the positive and negative effects across all outcome categories.

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Cemiplimab (kutanes Plattenepithelkarzinom, adjuvant); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 19.06.2026]. URL: https://doi.org/10.60584/A25-155.

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Cemiplimab (kutanes Plattenepithelkarzinom, adjuvant); Addendum zum Projekt A25-155 (Dossierbewertung) [online]. 2026 [Accessed: 19.06.2026]. URL: https://doi.org/10.60584/A26-44.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Cemiplimab (Neues Anwendungsgebiet: kutanes Plattenepithelkarzinom, nach Resektion und Strahlentherapie, adjuvante Therapie) [online]. 2026 [Accessed: 19.06.2026]. URL: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1293/.

English translations for this project are published at https://www.iqwig.de/en/projects/a25-155.html and https://www.iqwig.de/en/projects/a26-44.html.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237
50679 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
Email: info@iqwig.de
Internet: www.iqwig.de